高级检索
    杨慧, 张俊. 意义不止当下,路漫漫其修远: 评纳武利尤单抗联合XELOX/FOLFOX方案在HER2阴性晚期胃癌一线治疗中的应用和影响[J]. 循证医学, 2021, 21(5): 262-265. DOI: 10.12019/j.issn.1671-5144.2021.05.002
    引用本文: 杨慧, 张俊. 意义不止当下,路漫漫其修远: 评纳武利尤单抗联合XELOX/FOLFOX方案在HER2阴性晚期胃癌一线治疗中的应用和影响[J]. 循证医学, 2021, 21(5): 262-265. DOI: 10.12019/j.issn.1671-5144.2021.05.002
    shu
    YANG Hui, ZHANG Jun. Meaningful, but Still a Long Way to Go: Comment on the Application and Influence of Nivolumab Combined With XELOX/FOLFOX in the First-Line Treatment of HER2-Negative Advanced Gastric Cancer[J]. Journal of Evidence-Based Medicine, 2021, 21(5): 262-265. DOI: 10.12019/j.issn.1671-5144.2021.05.002
    Citation: YANG Hui, ZHANG Jun. Meaningful, but Still a Long Way to Go: Comment on the Application and Influence of Nivolumab Combined With XELOX/FOLFOX in the First-Line Treatment of HER2-Negative Advanced Gastric Cancer[J]. Journal of Evidence-Based Medicine, 2021, 21(5): 262-265. DOI: 10.12019/j.issn.1671-5144.2021.05.002
    shu

    意义不止当下,路漫漫其修远: 评纳武利尤单抗联合XELOX/FOLFOX方案在HER2阴性晚期胃癌一线治疗中的应用和影响

    Meaningful, but Still a Long Way to Go: Comment on the Application and Influence of Nivolumab Combined With XELOX/FOLFOX in the First-Line Treatment of HER2-Negative Advanced Gastric Cancer

      摘要
      • HTML全文
      • 参考文献(5)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回